Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biochemical markers in multiple myeloma: a multivariate analysis.

B Simonsson1, C F Källander, G Brenning

  • 1Department of Internal Medicine, University Hospital, Uppsala, Sweden.

British Journal of Haematology
|May 1, 1988
PubMed
Summary

Serum beta 2-microglobulin (S-beta 2m) is the key predictor of survival in multiple myeloma patients. Hemoglobin (Hb) levels are the most significant factor influencing initial therapy response.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physical mobility, physical activity, and obesity among elderly: findings from a large population-based Swedish survey.

Public health·2017
Same author

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.

Leukemia·2016
Same author

A Randomized Comparison of Doxorubicin and Doxorubicin-DNA in the Treatment of Acute NonLymphoblastic Leukemia.

Leukemia & lymphoma·2016
Same author

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.

Leukemia·2015
Same author

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.

Leukemia·2015
Same author

Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.

Breast cancer research and treatment·2013

Area of Science:

  • Biochemistry
  • Clinical Oncology
  • Hematology

Background:

  • Multiple myeloma is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
  • Accurate prognostic markers are crucial for guiding treatment strategies and predicting patient outcomes.

Purpose of the Study:

  • To identify significant biochemical and clinical variables associated with survival and initial therapy response in multiple myeloma.
  • To establish a multivariate model for predicting prognosis in multiple myeloma patients.

Main Methods:

  • Analysis of 121 multiple myeloma patients.
  • Individual and multivariate analysis of biochemical markers (serum beta 2-microglobulin, thymidine kinase, lactate dehydrogenase, creatinine, albumin, calcium) and clinical factors (hemoglobin, ESR, M-component, light chains, immunoglobulin type, age, clinical stage).

Related Experiment Videos

Main Results:

  • Serum beta 2-microglobulin (S-beta 2m) demonstrated the strongest correlation with survival.
  • Hemoglobin (Hb) was the most significant predictor of initial therapy response, containing all relevant information in multivariate analysis.
  • Multivariate models identified S-beta 2m, age, and serum thymidine kinase (S-TK) as key prognostic factors; clinical stage III provided additional information.

Conclusions:

  • S-beta 2m is a primary prognostic indicator for survival in multiple myeloma.
  • Hb is a critical factor for predicting response to initial therapy.
  • A combination of S-beta 2m, age, S-TK, and clinical stage offers valuable prognostic information.